BNTX · BioNTech SE
$86.86
-1.42% last session
End-of-day data · close of 2026-10-26
Market cap
$22B
Enterprise value
$9B
Trailing P/E
—
Forward P/E
-18.3
Dividend yield
0.0%
Beta
1.25
Avg volume
1M
Employees
8K
Daily Change %
-1.42%
5 Days Change
2.23%
10 Days Change
0.74%
30 Days Change
-8.93%
60 Days Change
-20.52%
Month to Day Change
-7.41%
Year to Day Change
-5.81%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BNTX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-14
Latest call per bank · past 12 months
Morgan Stanley
Overweight$114
+29.4% vs priceCitigroup
Buy$125
+41.9% vs priceUBS
Buy$135
+53.2% vs priceWells Fargo
Overweight$140
+58.9% vs priceJefferies
Buy$138
+56.6% vs priceGoldman Sachs
Buy$142
+61.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Canaccord Genuity | Maintains | Buy | $136 → $132 |
| 2026-10-07 | Morgan Stanley | Maintains | Overweight | $115 → $114 |
| 2026-09-08 | BMO Capital | Downgrade | Outperform → Market Perform | $128 → $105 |
| 2026-08-31 | Canaccord Genuity | Maintains | Buy | $142 → $136 |
| 2026-08-05 | Citigroup | Maintains | Buy | $130 → $125 |
| 2026-08-05 | Evercore ISI Group | Maintains | Outperform | $135 → $130 |
| 2026-07-08 | Morgan Stanley | Maintains | Overweight | $126 → $119 |
| 2026-05-27 | UBS | Upgrade | Neutral → Buy | $117 → $135 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 36 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 11.7% below the 50-day MA ($98.36).
- bearish: Price vs 200-day MA: Trading 10.8% below the 200-day MA ($97.43).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.36) — short-term momentum is fading.
- bearish: 52-week range: Price is within 10% of the 52-week low ($83.89).
BNTX Price Chart
Loading chart for BNTX…
Fundamentals
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.